Prandial insulin
Insulin aspart (prandial)
INS_ASPART
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.75 (-2.88 to -0.41) | 0.90 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Semaglutide injection | MD 0.29 (-0.71 to 1.19) | 0.50 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.60 (-5.81 to 7.06) | 0.29 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Semaglutide injection | MD 6.99 (1.43 to 11.46) | 0.38 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.44 (0.03 to 5.08) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.33 (0.03 to 3.42) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.75 (1.59 to 13.85) | 0.24 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.50 (0.40 to 16.81) | 0.35 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.59 (0.64 to 9.99) | 0.24 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.94 (0.41 to 8.38) | 0.33 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 5.68 (-0.10 to 11.53) | 0.21 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 2.61 (-2.96 to 9.86) | 0.26 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.74 (-3.36 to 4.99) | 0.15 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.62 (-5.50 to 6.27) | 0.19 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.17 (-1.14 to 1.54) | 0.53 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.22 (-1.33 to 1.76) | 0.50 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.49 (-1.46 to 2.61) | 0.37 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.21 (-2.34 to 3.06) | 0.45 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.26 (0.83 to 1.96) | 0.35 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.28 (0.84 to 1.98) | 0.31 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.45 (0.15 to 1.25) | 0.83 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.42 (0.13 to 1.21) | 0.82 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.19 (0.07 to 0.43) | 0.94 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.23 (0.08 to 0.65) | 0.86 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.29 (0.10 to 0.78) | 0.91 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.32 (0.09 to 1.04) | 0.87 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.67 (0.36 to 1.23) | 0.83 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.73 (0.37 to 1.41) | 0.76 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.43 (0.18 to 140) | 0.24 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.07 (0.00 to 0.80) | 0.90 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.06 (0.00 to 0.68) | 0.87 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 2.51 (0.09 to 87.99) | 0.47 |
Trials
- S0029912023 · 220 randomized · 13.04 weeks
- SUSTAIN 11Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes2018 · 1,748 randomized · 52 weeks
- SIMPLEThe Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study2014 · 120 randomized · 26 weeks